Table 2.

Comparison of efficacy and loss of efficacy in both groups

	Infliximab original Group	95%CI	CT-P13 Group	95%CI	P value	Rate difference (95%CI)
Basal global remission	76/98 (77.6%)	66.8-86.3	81/98 (82.7%)	74.6-90.7	0.474	-0.173-0.071
Global remission 12 mo	66/93 (71%)	61.2-80.7	60/88 (68.2%)	51.1-71.4	0.806	-0.117-0.173
Basal remission CD	51/67 (76.1%)	65.2-87.1	56/67 (83.6%)	73.9-93.2	0.389	-0.225-0.076
Remission 12 mo CD	45/65 (69.2%)	57.2-81.2	42/62 (67.7%)	55.3-80.2	0.992	-0.163-0.192
Basal UC remission	25/31 (80.6%)	62.5-92.5	25/31 (80.6%)	62.5-92.5	0.748	-0.29-0.229
Remission 12 mo UC	21/28 (75%)	57.2-92.8	18/26 (69.2%)	49.6-88.9	0.866	-0.219-0.334

UC: Ulcerative colitis. CD: Crohn’s disease.